SFDA approves registration of ‘Anktiva’ for treatment of bladder and lung cancer

January 17, 2026January 17, 2026

Saudi Gazette reportRIYADH — The Saudi Food and Drug Authority (SFDA) has granted conditional approval for Anktiva (nogapendekin alfa inbakicept) in combination with immunotherapy for adult patientsSaudi Gazette reportRIYADH — The Saudi Food and Drug Authority (SFDA) has granted conditional approval for Anktiva (nogapendekin alfa inbakicept) in combination with immunotherapy for adult patients

Previous PostSaudi Arabia Railways issues tender for 10 new passenger trains on Northern NetworkNext PostHail wins Guinness World Record with largest off-road production cars convoy